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Dietary selenium intake has been linked to reduced cancer risk, however the underlying
mechanisms are yet unknown. We question the commonly used practice of applying sele-
nium concentrations found in human blood to in vitro studies and evaluated the utility of bio-
markers, e.g., glutathione peroxidase 1 (GPx1) and thioredoxin reductase 1 (TrxR1), to deter-
mine appropriate selenium levels for in vitro work. Furthermore, we investigated the effects
of Se-methylselenocysteine (SeMSC) on prostate cancer cell migration and invasion. After
excluding cytotoxicity, we demonstrated that prostate cancer cell lines respond differently
to selenium treatment as observed through biomarker assessment. We found that the
maximum levels of GPx1 activity andTrxR1 expression were reached at lower selenium con-
centrations in LNCaP compared to PC3 cells, and PC3 compared to DU145 cells.Therefore
the use of selenium concentrations extrapolated from human studies for in vitro work may
be applicable when further informed using a readout of selenium repletion including use
of selenium responsive biomarkers. No effect on PC3 migration or invasion was observed
after long term SeMSC treatment; however a slight increase was found when treatment
was solely administered during the assay.The opposite could be observed when cells were
cultured under low serum conditions, with a significant increase in migration upon long term
but not upon acute SeMSC treatment.To conclude, these findings indicate that it is imper-
ative to study the selenium sensitivity of an in vitro model preferably using biomarkers
before investigating any effects on biological processes, or before comparing models.
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INTRODUCTION
Selenium is an essential trace element and plays an important role
in protection against cardiovascular disease, inflammation and
inflammatory disorders, diabetes, infertility, and cancer (1). Sele-
nium regulates protein function through its incorporation into
selenoproteins as selenocysteine (1). Most selenoproteins have a
functional role that impacts on chronic diseases such as cancer
through the management of reactive oxygen species (ROS),present
in numerous antioxidant defense systems throughout the body (2).
It has become clear that there is a very narrow margin between
selenium deficiency and toxicity, with beneficial levels on health
being dependent on the form of selenium, level of exposure, and
selenium status (3). Selenium can be measured in whole blood,
blood fractions (plasma, serum, red blood cells), hair, nails, and
urine. Plasma selenium levels below 0.6µM (40–50 ng/ml) are
considered deficient, and risk of toxicity occurs at levels higher
than 2µM (160 ng/ml), with reports of toxic effects at concen-
trations higher than 3µM (250 ng/ml) (4–6). Plasma selenium
concentrations are considered to be adequate at 1.1–2µM (90–
160 ng/ml), when selenoprotein P levels reach a plateau and cancer
protective benefits may be maximized (7). Daily dietary recom-
mendations have traditionally been based on the quantity of
selenium required for optimal glutathione peroxidase 3 (GPx3) or
erythrocyte GPx1 activity in blood. As such the dietary reference
in the UK is set at 60µg/day for women and 75µg/day for men
although the mean intakes are 45–55µg/day (1). In the US intakes
are higher than in the UK, whereas in parts of China there are
extremes of intake (related to local soil conditions), with both
deficient and toxic levels (8).
The aim of the present work was to interrogate the value of
extrapolating selenium concentrations found in human blood to
in vitro studies. The use of biomarkers is now common practice in
clinical nutrition studies and sometimes in animal models. How-
ever, in in vitro models, the amount of selenium used is at best
extrapolated from “physiological relevant” serum concentrations.
We evaluated the use of biomarkers such as glutathione peroxi-
dase 1 (GPx1) and thioredoxin reductase 1 (TrxR1) as markers
for selenium repletion and this within the non-toxic range of sele-
nium treatment. GPx1 is one of the most abundant selenoproteins
and its expression is highly sensitive to a fall in selenium supply
and oxidative stress (9, 10). In general, enhanced GPx1 function
is associated with increased protection against oxidative damage
(11). TrxR1 is a highly selenium sensitive selenoprotein (11) and is
of interest as a selenium biomarker for prostate cancer cells as it has
been shown to respond to selenium treatment past the repletion
point of GPx (12).
Further, we investigated the effect of selenium on cancer cell
motility using migration and invasion assays of PC3 cells. Cancer
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cells often have enhanced growth and metastatic potential. To
date, only a few studies have investigated the effect of selenium on
migration and invasion of cancer cells in vitro (13–17). Although
there are discrepancies between the findings from these stud-
ies, treatment with various selenium compounds has generally
resulted in a decrease in the migration and, in some instances,
the invasion of cancer cells. As no data have been published on
the role of selenium in cell motility of prostate cancer cell lines,
the aim of the present work was to determine the effect of Se-
methylselenocysteine (SeMSC) on the migration of PC3 cells and
their invasion through matrigel.
There are limited comparative data on the toxicity of selenium
compounds in cell systems, hence we compared the cytotoxicity of
selenomethionine (SeMet), SeMSC, and selenite in three different
prostate cancer cell lines (18–23). SeMet represents the major form
of selenium in plant crops, while SeMSC can be found in broccoli,
garlic, and onions, especially when grown under selenium-rich
conditions (24, 25). Sodium selenite is water-soluble and is the
most commonly used form in food and vitamin supplements (26).
In the present study the utility of GPx1 and thioredoxin reduc-
tase 1 as in vitro selenium biomarkers was assessed in three differ-
ent prostate cancer cell lines and the effects of selenium treatment
on migration and invasion of PC3 cells was investigated.
MATERIALS AND METHODS
CELL CULTURE
LNCaP, PC3, and DU145 are cell lines derived from prostate cancer
metastasis isolated from the lymph nodes, bone, and brain, respec-
tively. All cell lines were procured from the American Type Culture
Collection bank (ATCC) and were maintained in Dulbecco’s Mod-
ified Eagle Medium/F12 (DMEM/F12) plus GlutaMAX™ (2.5 mM
l-Alanyl-l-Glutamine) with Hyclone-defined fetal bovine serum
(FBS, Thermo Scientific) and 1% penicillin–streptomycin (peni-
cillin 5000 units/ml, streptomycin 5000µg/ml, Gibco). The use of
Hyclone-defined FBS containing 380 nM total selenium, according
to manufacturer’s batch analysis, resulted in control samples con-
taining 38 nM or 10 nM total selenium under respectively 10% or
low 2.5% serum conditions. Low 2.5% serum culture conditions
were achieved by gradually reducing the amount of FBS. Selenium
treatment of several cell lines with selenite (Sigma-Aldrich), SeMet
(Sigma-Aldrich), or SeMSC (Sigma-Aldrich), was conducted for a
duration 48 h for short-term (acute exposure) or for 30 days which
allows longer term adaptation to occur.
PROTEIN EXTRACTION AND QUANTIFICATION
Cells were lysed at 80% confluency in 100 mM Tris lysis buffer pH
7.4 supplemented with 0.1% Triton X-100 and a protease inhibitor
cocktail (Roche). Cell pellets (6× 106 cells) were ground in 350µl
lysis buffer using a microcentrifuge tube pestle (Sample grinding
kit, GE Healthcare) and sonicated on ice (Biologics 300V/T with
3.9 mm tip, 40% power, 50% pulse, 7 min). After sonication, sam-
ples were centrifuged at 12,000× g, 4°C for 10 min, and stored at
−80°C. The protein concentration was quantified using a BCA
assay kit (Thermo Scientific) and absorbance was read at 562 nm.
MTT VIABILITY ASSAY
Cells were seeded at 10× 103 cells/well in a 96-well tis-
sue culture plate. After 24 h, the cells were treated with 10
different concentrations of selenium supplementation for 48 h.
The treatment was removed and cells were incubated with MTT
(0.45 mg/ml, Sigma) at 37°C for 2 h. Finally cells were incubated
with DMSO (Fisher) at room temperature for 5 min. Changes in
metabolism were used as an indicator of cell viability which was
calculated from absorbance values at 550 and 630 nm (wavelength
correction) using the MARS analysis software (BMG Labtech,
version 1.11).
GPx ENZYME ACTIVITY ASSAY
Glutathione peroxidase activity was assessed using an assay mix-
ture of 100 mM Tris, 5 mM EDTA, 1.5 mM sodium azide, 0.1% Tri-
ton X-100, 0.25 mM NADPH (Sigma), 3 mM glutathione (Sigma),
and 1 unit glutathione reductase (Sigma). Cell extracts were used
at 0.5–2 mg/ml according to the enzyme activity of each cell line.
The rate of increase in absorbance at 340 nm was monitored at
37°C every 10 s for 15 min after the addition of 2.5 mM t -butyl
hydroperoxide (Sigma). One unit GPx activity was defined as the
oxidation of 1µmol of NADPH per minute and was related to the
protein content of the cell lysate. Using the slope as determined
by the MARS software (BMG Labtech V1.11), GPx activity was
calculated using the following equation with 0.00379µM−1 as the
NADPH extinction coefficient, slope as Delta A 340/min, and units
GPx in micromoles NADPH/min:(
Well volume
Sample volume
)
×
(
Slope
0.00379 µM−1
)
= Units GPx
g protein extract
TrxR1 WESTERN BLOT
Cell lysates were resuspended in 4×NuPAGE® LDS sample buffer
(Invitrogen) and resolved on a NuPAGE® Novex 4–12% Bis-Tris
mini gel (Invitrogen) at 200 V before transfer at 30 V onto a
PVDF membrane (Immobilon-FL, Millipore). The membranes
were blocked for 1 h in protein-free T-20 TBS blocking buffer
(Thermo) at room temperature. The membranes were probed
overnight at 4°C with rabbit anti-TrxR1 antibody at 1:1000 (Santa
Cruz) and chicken anti-GAPDH at 1:20,000 (Millipore). The sec-
ondary donkey anti-rabbit (Li-Cor) and donkey anti-chicken (Li-
Cor) infrared labeled antibodies diluted at 1:10,000 and 1:20,000
in 50% blocking buffer/10 mM PBST/0.1% SDS were used for
2 h at room temperature. Bound antibodies were visualized and
quantified using the Odyssey imaging system (Li-Cor).
MIGRATION AND INVASION ASSAYS
Prior to the assays, 10% serum cultured PC3 cells were labeled
with 10 mg/ml DilC12 stain (BD Biosciences) in phenol-red free
DMEM/F12 GlutaMAX™ (Invitrogen) media for 1 h at 37°C. In
addition, the assays were also performed using cells which were
adapted to low 2.5% serum levels for 30 days. After labeling, the
cells were resuspended in serum free, phenol-red free media, and
loaded on top of an 8µm BD Matrigel™ Matrix-coated membrane
of a BD BioCoat™ Tumor Invasion System (BD Biosciences).
Uncoated BD Falcon™ FluoroBlok™ 24-multiwell insert plates
were included as migration controls. Media containing 5% serum
was added to the bottom chamber to create a chemoattractant
gradient between the top and bottom chamber. The Fluoroblok
plates were covered with sterile gas permeable membrane (Axygen)
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and incubated in a 5% CO2 and 37°C controlled plate reader for
22–44 h. The number of cells migrating or invading was measured
every 5 min (544, 590 nm) and fluorescence units were collected at
endpoint and analyzed using the MARS software (BMG Labtech,
version 1.11).
STATISTICAL ANALYSIS
Statistical significance was determined using a two-tailed t -test,
and significance level was set at p≤ 0.05 or 0.005. Standard devia-
tions were shown as error bars. Curve fitting was performed where
possible using Graphpad Prism 5.
RESULTS
EFFECT OF SELENIUM TREATMENT ON CELL VIABILITY IN VITRO
Epidemiological data have demonstrated a narrow margin
between selenium deficiency and toxicity. It is therefore impor-
tant to determine the range of selenium concentrations which
correspond to non-toxic, optimal levels in vitro systems when
investigating the effects of selenium on biological processes. In
order to demonstrate minimal toxicity of the selenium com-
pounds and concentrations used,MTT viability analyses of SeMSC
(0.5–200µM), SeMet (0.5–200µM), and sodium selenite (0.5–
50µM) were performed. The LC50/48 h of SeMSC was recorded
and compared to those of SeMet and sodium selenite (Table 1;
Figure 1).
After treatment with SeMSC we observed a LC50/48 h value of
400–800µM in PC3, 200µM in LNCaP, and 150µM in DU145
cells. Overall, in comparison to the commonly used selenium com-
pounds, SeMSC was found to be 5–10 times less toxic than the
sodium selenite but 2 times more toxic than the SeMet. Among the
three cell lines studied, PC3 cells were considerably less sensitive
to selenium toxicity. These findings are in line with the published
literature on selenium toxicity in prostate cancer in vitro when
Table 1 | LC50/48h concentrations of SeMSC, SeMet, and sodium
selenite.
SeMet (µM) SeMSC (µM) Sodium selenite (µM)
PC3 >800* 606.3† 7.9†
LNCaP 400* 175.6† 4.5†
DU145 300* 141.7† 3.5†
The LC50 values for the various prostate cancer cell lines were determined at 48 h
using the MTT viability assay. †Calculated using Graphpad Prism 5 curve fitting.
*Estimate from lower concentrations. LC, lethal concentration.
FIGURE 1 | MTT viability assay of selenium treated prostate cancer cell
lines. Selenium treatment was maintained for 48 h in 10% serum containing
conditions and viability was assessed through comparison with metabolic
rate of untreated controls (38 nM total selenium from FBS). (A) SeMet
(B) SeMSC (C) Selenite. Data represents average of six biological replicates;
error bars represent ±SD.
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considering the different methodologies, compounds, cell lines,
and treatment duration used (18–21).
Using identical culture and treatment conditions for all three
cell lines, we found that DU145 cells were more sensitive to sele-
nium toxicity than LNCaP and PC3 cells. These data indicate that
the concentrations used in the biomarker activity and invasion
assays are in the non-toxic range and hence do not adversely affect
or interfere with the respective results.
EFFECT OF SELENIUM TREATMENT ON SELENIUM BIOMARKERS
IN VITRO
Glutathione peroxidase 1 activity is often used as a biomarker of
selenium status and reaches a plateau at plasma selenium concen-
trations of 1.3µM (80–120 ng/ml) (27). In cell culture,GPx1 activ-
ity is reported to plateau at 30–50 nM selenite and 250–2000 nM
SeMet (28). However, various in vivo studies have suggested that
GPx activity is not a sensitive or reliable biomarker at moderate
to high selenium intakes. A rise in serum selenium concentration
(from 123 to 196 ng/ml) has been associated with an increase in
prostate tissue selenium concentration (1.4–1.6µg/g) although no
effect on GPx activity was observed in prostate tissue (5). These
discongruent patterns might have been caused by a high baseline
selenium concentration in the study population. Another study
published findings that showed a positive correlation between
GPx activity in prostate tumor tissue and Gleason score, while
an inverse correlation was observed with Selenium binding pro-
tein 1 (29). TrxR1 has been associated with increasingly aggressive
tumors (30) and has even shown potential as an anti-cancer tar-
get (31). As part of a New Zealand prostate cancer selenium trial,
the relationship between serum selenium concentration and both
TrxR and GPx activity in erythrocytes of 43 participants, aged
50–75 years, with PSA levels above 4 ng/ml, and a negative biopsy
was investigated (12). This study reported a positive correlation
between baseline serum selenium concentrations (59–128 ng/ml)
and both enzyme activities. However, after supplementation (200
or 400µg/day from selenium-enriched yeast) a 66% increase in
serum selenium concentration was reflected in an 80% increase
in TrxR activity but not by an increase in GPx activity. This find-
ing suggests that TrxR activity might be a good biomarker at high
selenium levels. Hence, we investigated GPx activity and TrxR1
protein expression as selenium biomarkers in LNCaP, PC3, and
DU145 cells in response to 48 h or 30 day treatment with SeMSC
and SeMet.
Effect of SeMSC and SeMet dose-response adaptation on GPx
activity under 10% serum culture conditions
As different selenium compounds and culture conditions variably
affect the selenium status of the cell lines it is important to note
that the blood selenium status and biomarker plateau may not
necessarily translate to the appropriate in vitro concentration of
selenium (32). We measured the GPx activity in LNCaP, PC3, and
DU145 cells following 30 day long term exposure and adaptation
to SeMSC (500 and 2000 nM) and SeMet (500 nM) to determine
the maximum GPx activity and the selenium dose at which this
occurs.
Significantly different responses in GPx activity were observed
between the three cell lines after exposure to different selenium
concentrations (Figure 2A). In LNCaP cells, neither SeMSC nor
SeMet induced a significant increase in GPx activity. GPx activity
levels were elevated, although not significant, to a maximum of
19.6± 1.9 U/g after treatment with 500 nM SeMSC compared
to control treatment (17.4± 0.4 U/g), whereas SeMet did not
affect activity levels. These findings might indicate that LNCaP
cells are replete at the selenium concentration (38 nM total sele-
nium) used in the control treatment. In PC3 cells, a signif-
icant 1.4-fold increase in GPx activity (p= 0.003) was found
between the control condition (5.1± 0.3 U/g) and 500 nM SeMSC
treatment (6.9± 0.4 U/g), with a further, although not statisti-
cally significant, increase after treatment with 2000 nM SeMSC
(7.4± 0.9 U/g). Using 500 nM SeMet a significant increase in GPx
activity (11.7± 1.6 U/g) was observed compared to the control
(5.1± 0.3 U/g, p= 0.002). In DU145 cells, high concentrations
of SeMSC, up to 2000 nM, were required to induce a 3.9-fold
increase in GPx activity (1.3± 0.1 U/g, p< 0.001). Even higher
SeMSC concentrations may be required to obtain maximum GPx
activity as there was a large difference in activity levels between
treatment with 500 and 2000 nM SeMSC. Treatment with 500 nM
SeMet increased GPx activity to 1.6± 0.1 U/g.
Comparison of GPx activity levels between SeMet and SeMSC
treatments revealed significant 1.7- and 5.3-fold higher levels at
500 nM SeMet compared to 500 nM SeMSC for PC3 and DU145
cells respectively. The GPx activity at 500 nM SeMet was even
higher than that at 2000 nM SeMSC for both cell lines, suggesting
that SeMet might have a more profound effect on GPx activity in
these cells. A previous study comparing the Gpx inducing poten-
tial of selenium compounds has demonstrated a GPx1 plateau in
LNCaP cells at 30 nM selenite, at 50 nM selenate, and at 250 nM
SeMet (28). In PC3 cells a plateau occurred at 40 nM selenite, at
500 nM selenate, and at 2000 nM SeMet. The authors also observed
that GPx1 RNA expression was modulated to a similar extent. Dis-
crepancies between their findings and our data might partly be due
to differences in assessment methods (activity assay versus western
blot densitometry) and culture conditions, including the culture
media and selenium content of the control media. Nevertheless,
in accordance to our SeMSC findings they report a higher SeMet
induced maximum GPx value in LNCaP cells compared to PC3
cells.
The baseline GPx activity was significantly different between
the three cell lines, even when grown under identical conditions.
Compared to PC3 and DU145 cells, 3-fold and 40-fold higher GPx
activity levels were found in LNCaP cells. The activities under con-
trol conditions were 89, 70, and 31% of the maximum GPx activity
of SeMSC-treated LNCaP, PC3, and DU145 cells, respectively
(Figure 2A), supporting the hypothesis by Rebsch and Colleagues
that GPx activity might not be the optimal selenium biomarker for
comparison of prostate cancer cell lines at higher selenium con-
centrations (28). The GPx1 activity values observed in PC3 and
DU145 control conditions were similar to those published by Jung
et al. who compared the levels of different antioxidant enzymes in
LNCaP, PC3, and DU145 cells (33). However, they found LNCaP
GPx activity values of about half of those observed in our study
which might be explained by differences in cell culture conditions
such as the media formulation or the confluency of cells at time
of harvesting.
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FIGURE 2 | GPx1 activity in prostate cancer cell lines. GPx activity was
expressed as a percentage compared to the activity at GPx plateau for
cells maintained in (A) 10% serum after 30 day selenium adaptation to
SeMSC or SeMet (B) 2.5% serum after 48 h of SeMSC treatment
(C) 2.5% serum after 30 day selenium adaptation to SeMSC. Data
represent average of three biological and three technical replicates, error
bars±SD. *Significant increase compared to previous concentration of
SeMSC, †significant increase compared to equal SeMSC concentration
p<0.05. Lines represent curve fit using Michaelis–Menten formula
[Graphpad Prism 5, y = (V max ×X )/(K m +X )] with (B) LNCaP, V max =7.38,
K m =9.37, and PC3, V max =2.27, K m =33.77, and (C) LNCaP, V max =24.43,
K m =8.71, and PC3, V max =4.68, K m =658.8.
Effect of acute and long term adaptation to SeMSC dose on GPx
activity under low serum culture conditions
The effect of culture conditions on GPx activity was further
explored in cells adapted to low serum conditions (2.5% serum)
containing low baseline selenium levels (10 nM total selenium).
The impact of both long- (30 days) and short-term (48 h) expo-
sure to SeMSC was investigated to determine GPx activity steady
state levels (Figures 2B,C).
Differences were found in the maximum GPx activity levels
as well as in the concentration of selenium at which this GPx
plateau occurred. LNCaP cells showed the highest GPx activity
(7.7± 0.02 U/g) with a 2-fold increase compared to the control
condition (3.8± 0.1 U/g, p< 0.001), and reached GPx repletion
at a lower SeMSC supplementation concentration (100 nM) com-
pared to the other cell lines. In PC3 cells, the repletion point for
GPx activity (2.3± 0.0 U/g) was reached at 500 nM SeMSC. The
GPx activity of the DU145 control condition was 4.5- and 19-fold
lower than those of PC3 and LNCaP cells. The GPx activity sig-
nificantly (p< 0.001) increased between 500 nM (0.4± 0.0 U/g),
1000 nM (1.0± 0.0 U/g), and 2000 nM SeMSC (1.7± 0.1 U/g).
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Comparing the three cell lines, the GPx activity of the respective
control conditions were 87% lower than the maximum activity for
DU145, 62% for PC3, and 50% for LNCaP cells. The maximum
GPx activities correspond with the V max of the Michaelis–Menten
curve fit whenever it was possible to calculate these (LNCaP
7.37± 0.15 U/g, PC3 2.27± 0.08 U/g).
Long term adaptation of cells under low serum conditions
resulted in even greater changes in GPx activity in LNCaP
cells (Figure 2C). A GPx plateau was reached at 30 nM SeMSC
with a >3-fold higher GPx activity (25.7± 1.7 U/g) compared
to the maximum GPx activity (7.7± 0.02 U/g) observed under
short-term treatment. Conversely, the maximum GPx activity
(1.5 U± 0.05/g) in DU145 cells was found to be lower than the
maximum activity under short-term treatment (1.7± 0.1 U/g). In
PC3 cells, maximum GPx activity (3.5± 0.3 U/g) was obtained
at 2000 nM SeMSC which was not statistically different from the
activity at 1000 nM SeMSC (2.8± 0.3 U/g). Comparing the three
cell lines again, the GPx activity of the control conditions were
68–91% lower than their respective repletion point. The maxi-
mum observed GPx activities correspond with the V max of the
Michaelis–Menten curve fit whenever it was possible to calculate
these (LNCaP 24.4± 0.1.9 U/g, PC3 4.7± 0.4 U/g). Longer term
adaptation for 30 days to SeMSC treatment under low serum con-
ditions caused lower SeMSC concentration to yield maximum
GPx activity in LNCaP cells while higher concentrations were
required in PC3 and DU145 cells (Table 2). When comparing
10 and 2.5% serum conditions, it is apparent that the selenium
content of serum can obscure an increase in GPx activity after
long term selenium treatment. In particular, LNCaP cells show no
increase in GPx activity under 10% serum containing conditions
while only a small increase could be observed for PC3 cells com-
pared to a pronounced increase in GPx activity under low serum
conditions.
Effect of acute SeMSC treatment on TrxR1 expression under low
serum culture conditions
To the best of our knowledge, only one study to date has inves-
tigated the effect of selenium treatment on TrxR activity in
prostate cancer cell lines. In this work no change in TrxR activity
was reported using physiologically relevant doses of selenium in
LNCaP and PC3 cells (19). High selenite doses (>5µM) resulted
in a decrease in TrxR activity. However, in the normal prostate
BPH-1 cell line an increase in TrxR activity was observed using
selenite treatment compared to control. TrxR1 has recently been
shown to respond to both selenium and Iberin treatment (34). In
accordance, we found that treatment of Caco-2 cells with 25 and
200 nM SeMSC resulted in a 1.4- and 1.5-fold increase of TrxR1
expression respectively, while combination treatment of 200 nM
SeMSC with 6µM Iberin resulted in a 2.1-fold increase (data not
shown). Western blotting revealed that a high molecular weight
form of TrxR1 was more selenium and Iberin responsive after 48 h
treatment than the 55 kDa lower molecular weight form. How-
ever, the identity and function of this high molecular weight form
remains unknown.
We studied the TrxR1 response in DU145, LNCaP, and PC3
cells exposed to SeMSC treatment under low serum conditions
(Figure 3). Under 2.5% serum culture conditions, short-term
Table 2 | SeMSC concentrations at which GPx activity plateaus.
Time Serum (%) SeMSC (nM)
at GPx
plateau
Max GPx
activity
(U/g)
Vmax (U/g)
LNCaP 30 days 10 ctrl (38) 19.6 n.a.
48 h 2.5 100 7.4 7.37±0.15
30 days 2.5 30 25.7 24.4±0.1.9
PC3 30 days 10 500 7.4 n.a.
48 h 2.5 500 2.3 2.27±0.08
30 days 2.5 1000 2.8 4.7±0.4
DU145 30 days 10 ≥2000 1.3 n.a.
48 h 2.5 ≥2000 1.7 n.a.
30 days 2.5 ≥2000 1.5 n.a.
Maximum observed GPx activity of LNCaP, PC3, and DU145 cells was assessed
using a GPx activity assay and Vmax was calculated using Michaelis–Menten curve
fitting in Graphpad Prism 5.
n.a., not available; GPx, glutathione peroxidase.
treatment for 24 h of DU145 cells with 100 nM SeMSC induced
a 2.1-fold increase in expression, reaching a plateau for the low
molecular weight form of TrxR1. Looking at the high molecu-
lar weight form, a maximum fold increase of 2.9 was obtained
after 24 h treatment with 2000 nM SeMSC, however this cannot
be established with certainty as being the plateau point. The high
molecular weight TrxR1 was found to be more strongly expressed
than the low molecular weight form in both normal and low serum
cultured DU145 cells. Low serum culture conditions revealed a
maximum expression of the high molecular weight TrxR1 form
in LNCaP cells after treatment with 200 nM SeMSC. Surprisingly,
this 2.5-fold increase in expression is reduced to 1.4-fold at SeMSC
concentrations higher than 200 nM. In contrast with the data
obtained from the DU145 cells but in accordance with those from
the Caco-2 cells, the lower molecular weight form shows a stronger
expression than the higher molecular weight form. In low serum
cultured PC3 cells, repletion of TrxR1 expression can be seen for
both the high and low molecular weight form after 24 h treatment
with 500 nM SeMSC with a 1.6- and 1.1-fold increase respectively.
Similar to the LNCaP cells, TrxR1 expression decreased at SeMSC
concentrations higher than those of the plateau point. In accor-
dance with the DU145 cells, but not LNCaP and Caco-2 cells,
the high molecular weight TrxR1 form shows overall a stronger
expression than the low molecular weight form.
When comparing the SeMSC levels required for TrxR1 reple-
tion, we found that the various prostate cancer cell lines respond
differently (Table 3). Lower concentrations of selenium were
needed for LNCaP cells than for PC3 cells and for PC3 cells than
for DU145 cells, which is in agreement with the results of the
GPx activity assays. These findings are also in agreement with pre-
viously published data on TrxR activity in these cell lines. For
instance, PC3 cells have been shown to have a more efficient
antioxidant system including a higher TrxR activity than LNCaP
cells, while DU145 cells have a slightly higher TrxR activity than
PC3 cells (31, 35). It might be of interest to study the TrxR1 sele-
nium responsiveness in long term low serum conditions in more
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FIGURE 3 |TrxR1 expression in prostate cancer cell lines. Cell lines
were cultured in either low serum (2.5%) media containing 10 nM of total
selenium (control) or media supplemented with 30–2000 nM SeMSC for
48 h. (A) Representative image of western blot showing TrxR1 protein
bands in green and loading control GAPDH in red. (B–D) Quantification of
TrxR1 expression normalized to GAPDH and expressed as percentage of
control with (B) LNCaP, (C) PC3, (D) DU145, no technical or biological
replicates.
detail. Hereby a TrxR1 activity assay might be a better approach for
this purpose since measurement of biomarker activity is function-
ally more relevant compared to biomarker expression and western
blotting is a less accurate method for quantification. Furthermore,
it is imperative that the nature and relation of the two TrxR1 forms
are explored in future studies.
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Table 3 | SeMSC concentrations at whichTrxR1 expression plateaus as
determined by western blotting.
Time (h) Serum (%) SeMSC (nM) atTrxR1 HMW
band repletion
LNCaP 48 2.5 200
PC3 48 2.5 500
DU145 48 2.5 ≥2000
HMW, higher molecular weight.
EFFECT OF SeMSC TREATMENT ON THE MIGRATION AND INVASION OF
PC3 CELLS
The effect of selenium treatment on the migratory and invasive
ability of prostate cancer cell lines has not been reported yet.
Furthermore, although SeMSC is a dietary relevant form of sele-
nium, no data on its effect on migration or invasion of cancer cells
are available. Therefore, we investigated the response of acute or
long term SeMSC treatment on both the migratory and invasive
behavior of PC3 cells (Figure 4).
We found that long term treatment with SeMSC showed no
effect on PC3 migration or invasion through Matrigel, whereas
acute treatment for the duration of the assay (22 h) resulted in
an increase in migration and invasion. A dose-response study
showed a 1.4-fold increase in migration across a range of 200–
5000 nM SeMSC (130.4± 16.1 FU/h, p= 0.002) as compared to
the control (93.0± 18.6 FU/h) (Figure 4A). On the other hand a
clear dose-response increase in invasion was observed (Figure 4B)
with 500 nM SeMSC (64.4± 13.7 FU/h) and 2000 nM SeMSC
(70.9± 8.0 FU/h) compared to control cells (56.1± 4.4 FU/h).
In addition, both the migration and invasion assays were
repeated using low 2.5% serum cultured cells in order to
achieve lower baseline selenium concentrations and a greater
chemoattractant gradient. In contrast to the results obtained
from 10% serum cultured cells, long term treatment under 2.5%
serum containing conditions resulted in an increase in migra-
tion whereas no difference was found with acute treatment
(Figure 4C). More specifically, a significant 1.9-fold increase in
migration (2085.1± 188.1 FU/h, p= 0.0017) was observed with
2000 nM SeMSC long term treatment compared to the control
condition (1078.8.1± 136.9 FU/h) or 2000 nM acute treatment
(1107.9± 117.6 FU/h). When investigating invasion, no differ-
ence was found for acute treatment whereas long term 2000 nM
SeMSC treatment resulted in a 1.8-fold increase as compared to
control treatment (data not shown). Therefore, we further inves-
tigated the effect of long term SeMSC treatment on PC3 invasion
under low serum conditions using a dose-response invasion assay
(Figure 4D). A 2.7- and 5-fold increase was found after treat-
ment with 500 nM (239.1± 24.3 FU/h, p= 0.003) or 1000 nM
(440.3± 99.9 FU/h, p= 0.007) SeMSC respectively. Surprisingly,
2000 nM SeMSC did not further increase invasion but instead
reduced invasion back to a 2.4-fold increase (209.0± 27.8 FU/h,
p= 0.006) compared to the control (88.0± 12.9 FU/h).
Our data demonstrate an increased migration and invasion of
PC3 cells after selenium treatment which are in agreement with
publications linking selenoproteins to the invasive potential of
macrophages (36). However, several reports have been published
showing that selenium has an inhibitory effect on the migration
and invasion of cancer cell lines using different forms and doses
of selenium. For instance, small amounts of the selenium metabo-
lite methylselenol (<1µM) have been shown to decrease both
HT1080 migration and invasion by 53 and 76%, respectively which
might be partly attributed to a decrease in expression of the active
form of MMP2. In contrast, no difference in invasion or migra-
tion was found after treatment with 5µM SeMet (14). On the other
hand, selenite treatment has been reported to inhibit the invasion
of HT1080 sarcoma cells but not their migration or adhesion (13).
Further, selenite treatment has been shown to reduce expression
of various MMPs in HT1080 sarcoma cells and biopsy derived
glioma cells, while no effect on MMP expression was observed in
HT1080 cells after selenate treatment. In another study, B16F10
murine melanoma cells treated with selenite showed a decreased
migration in a wound healing assay and transwell migration assay.
The authors suggest the reduction in migration might be caused
by a decreased HIF-1 and VEGF expression, regulated through a
decreased IL-18 expression (17).
DISCUSSION
The present work questions the commonly used practice of using
selenium concentrations found in human blood for in vitro studies
and evaluated the utility of biomarkers such as GPx1 activity and
TrxR1 protein expression to determine appropriate selenium levels
for in vitro work. We studied the use of GPx1 and TrxR1 as bio-
markers of SeMSC treatment under different culture conditions
and found that GPx activity and TrxR1 protein expression showed
a similar selenium repletion pattern and that the effects of sele-
nium treatment on both biomarkers were more pronounced under
low 2.5% serum containing conditions. However, we noticed that
the maximum levels of GPx1 activity and TrxR1 expression were
reached at lower selenium concentrations in LNCaP cells com-
pared to PC3 cells, and in PC3 cells compared to DU145 cells.
As such we have been able to demonstrate that one particular
physiological relevant dose of selenium, extrapolated from con-
centrations observed in human blood,can elicit different responses
in different prostate cancer cell lines. Therefore using a read-out of
selenium repletion such as selenium responsive biomarkers may
assist with the selection of which selenium concentration to use
in in vitro work. Further, we found no relation between the maxi-
mum biomarker level and the selenium concentration required to
reach that biomarker repletion. For example, LNCaP cells reach
the maximum GPx1 activity level at lower selenium concentra-
tions than the other cell lines but their maximum GPx1 activity
levels are higher than those of PC3 or DU145 cells. Similarly, maxi-
mum protein expression of the high molecular weight TrxR1 form
was lower in LNCaP cells compared to PC3 cells, and lower in PC3
cells compared to DU145 cells while lower selenium concentra-
tions were required to result in TrxR1 repletion in LNCaP cells
compared to PC3 and DU145 cells.
The effect of SeMSC on the migratory and invasive behavior
of PC3 cells was examined under both normal and low serum
culture conditions. Selenium treatment induced an increase in
migration and invasion in long term low serum conditions. Fur-
ther studies are required to determine whether the increased
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FIGURE 4 | Migration and invasion of PC3 cells after selenium
treatment. Dose-response study of acute SeMSC treatment on
(A) migration of PC3 cells cultured in 10% serum containing media
(B) invasion of PC3 cells cultured in 10% serum containing media,
(C) migration of 10 and 2.5% serum cultured cells with acute or long
term adapted SeMSC treatment, (D) 44 h dose-response study of long
term/adapted SeMSC treatment on invasion of 2.5% serum cultured
cells. Bar charts represent average migration or invasion rate per hour
during the linear range of the 24 h assay, three biological replicates,
error bars ±SD. *p<0.01.
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invasion is a reflection of increased migration or a combination of
increased migration and remodeling of the extracellular matrix.
It is hereby important to determine the matrix stiffness as it has
been shown that tumor cells can invade extracellular matrices in
a protease-independent manner at relatively low matrix stiffness
(37). Future work is also needed to investigate which selenium
dependent/responsive proteins are involved in this process.
The results of this work indicate that it is essential to determine
the selenium sensitivity of an in vitro model before investigat-
ing the effects of selenium compounds on biological processes,
or before comparing models. It also underlines that “golden stan-
dard” dose-response curves may not be the best method to deter-
mine “physiologically relevant” in vitro micronutrient concentra-
tions. It might be more advisable to use appropriate biomarker
assessment in future in vitro studies.
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